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Abstract
Rheumatoid arthritis (RA) being a chronic inflammatory disease can be affected 
by both genetic and environmental factors. Abnormal functioning of immune 
response is the main underlying cause of RA. A growing number of studies on 
related diseases uncovered that microRNA (miRNA) may influence the pathogen-
esis of RA, such as the promotion of proliferation of fibroblast-like synoviocytes 
and secretion of cytokines by highly expressed miRNAs. A large number of studies 
have reported the aberrant expressions of miRNAs during the entire phase of RA, 
from the preclinical to terminal stages. These dynamic changes can be potentially 
developed as a bio-marker for predicting the risk, diagnosis and clinical manage-
ment of RA. This chapter aims to summarize and discuss miRNAs’ roles and 
mechanisms in the process of RA development, differential diagnosis from other 
diseases, clinical management and refractory RA. Therefore, miRNA demonstrates 
future perspectives of diagnosis and treatment of clinical RA under the support of 
newly discovered theoretical basis.
Keywords: Rheumatoid arthritis, microRNA, bio-marker, diagnosis, refractory 
rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease, which causes joint defor-
mity and disability in patients. RA can occur at any age, particularly with a high 
incidence in women aged 30–50 [1]. It has been shown that the average lifespan of 
RA patients is 3 to 18 years shorter than that of healthy people [2]. Patients with RA 
have high mortality rate and extra-articular complications, such as cardiovascular 
diseases, becoming the greatest challenge [2]. Proliferation of synovial tissue, infil-
tration of inflammatory factors, imbalance of immunity system, and destructions 
of bone and cartilage are the main common pathological characteristics of RA [3]. 
However, the current understanding of RA etiology and pathology are far yet to be 
elucidated. Some opinions on RA etiology illustrated high risk factors including but 
not limited to gene background, gender difference, smoking, obesity and environ-
ment factors. During the last decade, a growing number of evidence has shown that 
the epigenetic mechanism of microRNA (miRNA) regulation contributes remark-
ably to RA pathogenesis.
MiRNAs belong to the non-coding RNA family, with about 22 nucleotides in 
length. The processes of miRNAs biogenesis and maturation take place in the nucleus. 
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The transcription of primary miRNAs (pri-miRNAs) from DNA molecule is the first 
step. After the recognition of these pri-miRNAs by an enzyme-protein complex, they 
are cleaved into precursor miRNAs (pre-miRNAs) with 70–100 nucleotides in length. 
Subsequently, the pre-miRNAs mature in the cytoplasm. Mature miRNAs finally 
regulate the post-transcriptional gene expression by binding to 3′-untranstaled region 
(3’UTR) of target mRNAs. Interestingly, the same gene can be modulated by multiple 
miRNAs, which collectively fine tune the expression of a certain gene. One-third of 
human genes of note is regulated by miRNA [4]. In addition, miRNAs participate 
the regulation of cell bio-behaviors, such as apoptosis, proliferation and invasion. 
Cytokine signaling is commonly known to regulate immune system, which is associ-
ated with the pathogenesis of RA. A large number of evidence showed that miRNAs 
participate in regulations of both innate and adaptive immunities by modulating 
cytokine signaling [5], such as the upregulations of miR-146 and miR-155 in LPS-
mediated innate immune response. Besides, a high expression level of miR-155 during 
thymic differentiation can increase Treg sensitivity to IL-2 and growth factors [6]. 
Given their important roles in cell regulation mechanisms and immunity responses, 
miRNAs have been frequently studied as potential bio-markers in diagnosis, target 
treatment, activity monitoring and therapy for RA disease. For example, during the 
early stages of undifferentiated arthritis, a high expression level of miR-483 was only 
found in patients who finally developed RA. In this chapter, we aim to review the 
different roles of miRNAs in RA, from the pathogenesis to clinical impact.
2. The functions of miRNA in RA development
Studies showed that synovial hyperplasia is a main pathological feature of 
RA, but the pathogenesis of RA is not fully elucidated. Fibroblast-like synovio-
cyte (FLS) is a major cell type found in the structure of synovial intima [7]. The 
most important step in the development of RA is the transformation of FLS by 
over-activation to RAFLS [8]. This process makes RA to present a characteristic, 
aggressive, and active clinical phenotype. It has been reported that RAFLS can 
recruit inflammatory cells through autocrine and paracrine methods to maintain 
the inflammatory state [7]. At the same time, compared with FLS, RAFLS has the 
characteristics of anti-apoptosis, predominant cell proliferation, invasion and 
metastasis. It also secretes inflammatory factors and promotes erosion of bone 
matrix (e.g. matrix metalloproteinases, MMPs). These secreted cytokines form a 
complex network system that affects each other, leading to an imbalance between 
synovial cell proliferation and apoptosis. This process therefore plays an important 
role in the progression of RA disease. Controlling the local proliferation of synovial 
cells and inducing their apoptosis are the key towards improvement of RA progno-
sis. Recent results showed that the activated phenotype of RAFLS is underpinned 
by epigenetic mechanisms—DNA methylation, histone modifications, and miRNA 
activity [9]. Newly emerging evidence suggested that dysregulated miRNA expres-
sions in RA synovial tissues, especially in RAFLS, may generally contribute to the 
molecular mechanism of disease. Comparing miRNAs expression in FLS between 
RA and osteoarthritis (OA) patients, miR-124a was only down-regulated in RAFLS 
[10]. Further experiments revealed that overexpression of miR-124a can to suppress 
RAFLS proliferation. In contrast to miR-124a, miR-203 was up-regulated in RAFLS 
compared with healthy FLS [11, 12]. Importantly, a high level of miR-203 can target 
NF-кB signaling pathway, promote IL-6 and MMPs secretions, and support RAFLS 
invasion and migration [12]. Besides, there are lots of miRNAs like miR-126 [13], 
miR-152 [14], miR-137 [15], miR-199a-3p [16] and miR-338-5p [17], controlling the 
development of RA via regulating RAFLS.
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RA is a well-known autoimmune disease, and both innate and adaptive immuni-
ties are the crucial steps for RA development. The role of miRNAs in regulating 
immune response has been reported in the literature. Alternations of miRNAs level 
can control the differentiation and immunological functions of various immune 
cells (monocytes, macrophages, and T cells) [18]. Many changes of miRNAs in 
these cells in RA patients have been reported. Chronically activated T cells are 
considered to be the trigger and key to RA. They are also the crucial link in inducing 
and aggravating RA immunological inflammatory response. On the one hand, they 
can induce activation of synovial macrophages and RAFLS. On the other hand, 
they contribute to T-Treg imbalance, which is a predominant mechanism of RA. 
A great number of studies have confirmed that there are various miRNA expres-
sions modulating T cells, such as miR-17 [19] and miR-146a [20]. Additionally, RA 
patients showed the increases of miR-16, miR-103a, and miR-222 in peripheral 
blood mononuclear cells (PBMCs) of RA patients, which promoted cytokine secre-
tion and disturb T-Treg balance [20]. The main miRNAs changes in different cells of 
patients compared with healthy controls were summarized in Table 1.
miRNA Regulation Sample Target Effects Ref.
miR-203 ↑ RAFLS NF-кB pathway IL-6↑, MMPs↑ [12]





↑ RAFLS NFAT5 proliferation↑, invasion↑, 
migration↑
[17]








FOXO3a IL-1β↑, IL-6↑,TNF-α↑, 
RAFLS proliferation ↑
[23]
miR-125b ↑ Synovial 
tissue
NF-κB pathway NF-κB mediated 
inflammation↑
[24]
miR-301a ↑ PBMCs PIAS3 Th17 differentiation↑,
cytokines↑
[25]






↓ RAFLS RB1 proliferation↑, apoptosis↓ [16]
miR-152 ↓ RAFLS ADAM10 proliferation↑, apoptosis↓ [26]










miR-192 ↓ RAFLS Caveolin 1 proliferation↑, apoptosis↓ [29]
miR-21 ↓ PBMCs STAT3 Th17↑, Treg↓ [30]




Changes in miRNA level in RA patients compared to healthy individuals.
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Having a clear understanding of miRNAs in the regulation of RA pathogenesis 
provides a new direction and strategy for RA treatment. In some animal models, 
miRNA mimics or silencers were used to regulate miRNAs expressions, thereby 
reversing the inflammatory reaction or joint damage. One example is the ame-
lioration of arthritis severity by reducing RAFLS’s population via intra-articular 
injections of miR-124 and miR-140 mimics [32, 33]. Furthermore, intra-peritoneal 
injection of miR-223 silencer showed the same effect on relieving arthritis severity 
[34]. In a CIA mice model, intravenous administrations of miR-146a [35] and miR-
708-5p [36] mimics were beneficial to prevent synovial hyperplasia and structural 
joint damage. Taken together, further investigations on the role of miRNAs in 
the pathogenesis of RA are of utmost importance for the treatment and delaying 
progression of RA, as well as developing novel targeted drugs.
3. MiRNA as a potential bio-marker in RA diagnosis
RA often begins insidiously with chronic developments of signs and symptoms, 
which may vary in intensity over many weeks. For most patients with new-onset 
RA, there is no obvious symptom in the early stage. Most of them show joint 
discomfort, which is difficult to distinguish RA from other diseases. In clinical 
practice, using rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) 
antibodies as diagnostic indicators are not sufficient [37]. Notably, the sensitivity 
and specificity of CCP antibodies in RA diagnosis were ~72% and ~92% respectively 
[38]. In some special cases, the CCP antibodies’ titers cannot reach the diagnostic 
thresholds. Moreover, genetic and environmental risk factors, together with sys-
temic immunization, affect the multi-stage development of RA. Identifying patients 
with RA and providing them a proper treatment can prevent 90% of patients in 
early-stage period from the progression of joint damage, and improve prognosis 
[39]. Therefore, there is an urgent need for identifying novel bio-markers to screen 
high-risk individuals and those with early stage of RA.
Single nucleotide polymorphism (SNP) variants residing within boundaries 
of genes encoding miRNAs is a common phenomenon, which may affect multiple 
major human disorders including RA [40]. The associations between miRNA-linked 
SNP and RA susceptibility have been studied extensively, such as rs11761231 in 
miR612, rs615672 in miR-541, rs2837960 in miR-509/602, rs6684865 in miR-181, 
rs9550642 in miR-1238 and rs6920220 in miR-519 [41]. Furthermore, the associa-
tion of variations of miRNA target genes with RA was exemplified by the discovery 
of SNP rs3027898 variant in miR-146a target gene, IL-1 receptorassociated kinase 
(IRAK-1), in RA patients. Collectively, the altera tions of miRNA gene and its target 
gene may increase the risk of developing RA.
The current understanding of the role of miRNAs in RA pathogenesis is limited, 
especially in the preclinical phase of RA. Some serum miRNA expression profiles 
from different people were evaluated to determine mechanisms underpinning the 
progression of RA onset in at-risk individuals. Among those miRNA expressions, 
only miR-103a-3p specifically increased in both RA patients and their seropositive 
first-degree relatives [42]. Patients who have symptoms of non-differential arthritis 
and a high serum miR-22 expression, finally developed RA [20]. Recently, a study 
examined circulatory miRNAs in RA patients, and further investigations illustrated 
that miR-221-3p, let-7d-5p, miR-431-3p, miR-130a-3p, miR-126-3p and miR-24-3p 
were significantly elevated in subjects “at risk” of developing RA [42]. Particularly, 
the elevated whole blood level of miR-103a-3p may become a powerful bio-marker 
for positive anti-citrullinated peptide antibodies (ACPA) individuals who have 
possibility to develop RA [42].
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Early stage RA (ERA) is defined as a disease duration less than 12 months. 
Several clinical studies have shown that ERA is a “window of opportunity” for 
disease-modifying anti-rheumatic drug (DMARD) therapy. Most patients at this 
stage will get long-term remissions or even complete remissions after systematic 
treatments. There are no golden diagnostic criteria in ERA to date, although this 
stage is important in clinical practice. During the last decade, multiple studies have 
demonstrated miRNA as a powerful tool for identifying molecular bio-markers 
for diagnosis in ERA. One highlight example is the analysis of highly expressed 
miR-22 level for distinguishing ERA patients from healthy individuals. Besides, 
miR-16, miR-146a, miR-223 and miRNA-155 were significantly down-regulated in 
ERA, and even lowered in established RA and healthy controls [43–45]. Generally, 
these miRNAs possibly improve early diagnosis of RA, especially in sero-negative 
patients.
RA diagnosis not only distinguishes the different phases of RA, but also differ-
entiates RA from other diseases, such as systemic lupus erythematousus (SLE), OA, 
multiple sclerosis (MS). Those diseases show similar symptoms to RA at the begin-
ning. Several studies have established analyses of different expressions of miRNAs 
among those indistinguishable diseases. Compared with healthy people, miR-146a 
and miR-155 were up-regulated in PBMCs of RA cases, and conversely, they had 
low expressions in PBMCs of SLE patients. In addition, miRNA-516a-3p, miRNA-
629 and miRNA-525-5p levels in PBMCs were significantly up-regulated in active 
SLE patients compared with those in healthy controls [46], but all these miRNAs 
have no specific expressions in RA patients. A recent study revealed that the expres-
sions of miR-371b-5p and miR-5100 also increased notably in the serum of SLE 
compared with healthy control and RA [47]. Further results revealed that miRNA-
346 in synovial tissues was only specifically elevated in RA [48]. Another seven 
miRNAs expressions in macrophages from patients with active RA and OA were 
also recently determined. MiR-99a, miR-100, miR-125b, miR-199-3p, miR-199-5p, 
miR-152 and miR-214 were down-regulated in macrophages in RA, while only 
miR-223 was up-regulated, compared with OA samples [49]. One more example is 
that the expression level of miR-34a-3p in RAFLS was generally lower than that in 
OAFLS [50].
Clearly, the observable changes in miRNAs and their molecular networks are of 
great values for determining new mechanisms related to the onset of RA, and also 
being used as bio-markers to predict the onset of preclinical RA and distinguish RA 
from other diseases.
4. The application values of miRNAs in RA clinical management
4.1 MiRNAs’ functions in activity monitoring of RA
The clinical management strategy of RA is “treat-to-target” [51]. In other 
words, patients can achieve remission or at least low disease activity state within 
6 months after effective treatment. If RA is insufficiently treated, extra-articular 
manifestations, such as the most frequently occurring rheumatoid nodules and even 
cardiovascular disease, may occur. Notably, this kind of cardiovascular disease is 
more closely associated with RA disease activity rather than traditional cardiovas-
cular risk factors. Furthermore, either manifestation of RA or complication of RA 
therapies (e.g. MTX and leflunomide) may lead to interstitial lung disease (ILD). 
This affirms the importance of activity monitoring from different aspects. Hence, it 
is necessary to develop new treatment strategies to retard RA progression by quick 
identification of conditions of RA remission before irreversible damage in joint 
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[39]. Currently, clinical indicators for RA activity monitoring are mainly based on 
clinical, laboratory and physical examinations, including simplified disease activity 
index (SDAI), disease activity score 28 (DAS28), erythrocyte sedimentation rate 
(ESR), C reaction protein (CRP) [52]. These indicators can be affected by subjective 
and objective factors, such as OA, fibromyalgia, and assessor’s experience. Both ESR 
and CRP are non-specific markers of inflammation, which are commonly affected 
by age, anemia, immunoglobulin and other factors. Therefore, these markers are 
not specific enough to RA patients. In view of the clinical demands, it is particu-
larly important to develop effective, precise and accurate biological markers for 
the evaluation of RA disease activity. Recent studies demonstrated that miRNA, a 
potential bio-marker, can be aberrantly expressed in different stages of RA progres-
sion, and thus allowing to monitor disease activity.
The correlations of miRNA levels (miR-125b, miR-21, miR-155, miR-346, 
miR-223 and miR-146a) in PBMC of RA patients with clinical characteristics and 
inflammation markers in RA patients were reported [53]. The expression levels of 
miR-146a and miR-155 were positively related to ESR, DAS28-CPR and cytokines 
(IL-1β, IL-17α, IL-6 and TNF-α). On the contrary, miR-21 was negatively related to 
DAS28 and those cytokines. Another study found that miR-125b was inversely cor-
related with RA activity [54]. The studies on miR-24 in patients’ serum with active 
RA disease uncovered that the miR-24 level increased with ESR and the DAS28 
[55]. Besides, miR-5571-3p and miR-135b-5p levels were found to be positively 
correlated with the disease activity and the inflammation level of RA [56]. Notably, 
the upregulated expressions of hsa-miR-432-5p and especially hsa-miR-194-5p in 
serum were associated with relapse in RA patients [57]. Increasing serum level of 
miR-223 was also found in remission patients several days before RA relapse [20]. 
Moreover, blood samples from 76 RA patients illustrated that lowering the levels 
of miR-548a-3p can promote RA relapse or increase disease activity [31]. In some 
cases, RA patients without proper treatment were accompanied by extra-articular 
symptoms, together with changes in some miRNAs levels. Analyzing abnormal 
expressions of miRNAs can assist in diagnosis of RA-related diseases. For example, 
some researchers collected miRNAs (e.g. let-7c-5p, miR-30a-5p, miR-30e-5p, 
miR-125a-5p, miR-126-3p, miR-126-5p, miR-425-5p, miR-3168, and miR-4446-3p) 
in a panel to predict cardiovascular disease in patients with RA [58]. Other findings 
found that differences in circulating miR-200c levels can distinguish RA patients 
with and without ILD [59]. More examples of the relationship between miRNAs 
expression and RA activity were shown in Table 2.
4.2 MiRNAs as potential bio-markers of therapeutic effectiveness
Despite the great progress of management of RA over the past three decades, 
anti-rheumatoid drugs (DMARDs), including conventional synthetic DMARDs 
(csDMARDs) and specific targeted DMARDs (e.g. biologic DMARDs, b-DMARDs, 
and targeted synthetic DMARDs, tsDMARDs), are still the first-line drugs for 
RA patients; however, a certain number of patients does not benefit from the 
treatments with multiple DMARDs [65]. For those patients, biological treatments 
targeting inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and 
interleukins (ILs), and B or T cells may give a better outcome [66–69]. Nevertheless, 
~20–30% of patients fail to respond to these biological agents. Therefore, it is 
necessary to explore novel bio-markers for predicting the clinical responses of RA 
patients to DMARDs or other therapies. The current indicators for assessing the 
therapeutic effectiveness involve inflammatory factors, disease activity and patient 
response outcome (PRO) [70]. These evaluation indicators, however, are easily 
affected by many factors, resulting in certain deviations. Emerging research showed 
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that the prediction of RA treatment was possibly achieved by monitoring the 
alterations of miRNA levels. This encourages the development of novel therapeutic 
strategies for RA via identifying molecular mechanisms of miRNAs.
Several findings demonstrated that almost all miRNAs expressions were 
changed during therapy. Using MTX significantly decreased the expressions of 
miR-155 and miR-146a, but increased the expression of miR-34 in rat tibiotarsal 
tissues [71]. Clinical research proved that RA patients who responded to MTX had 
lower expressions of specific miRNAs, including not only hsa-miR-155-5p and 
hsa-miR-146a-5p, but also the newly reported hsa-miR-132-3p [60]. The circulat-
ing miR-10a in RA patients was markedly decreased, but was up-regulated when 
treated with MTX [72].
Although miR-223 and miR-16 were shown to be overexpressed in synovial tis-
sues of RA patients, their expressions were decreased after treated with csDMARDs 
[62]. More importantly, disease severity was reduced when miR-223 was silenced 
in experimental arthritis [34]. Another finding demonstrated that miR-125b 
expression showed more alternations between patients in terms of good response 
and poor response [73]. Its expression was relatively low in patients with early RA, 
but increased markedly after 3 months of conventional therapy [54]. Thus, these 
miRNAs could become potential bio-markers in both csDMARD and bDMARD 
therapies.
Furthermore, some miRNAs were good candidates for predicting the treatment 
of RA with anti-TNF therapy. A placebo-controlled, double-blind and prospective 
study of patients with early RA showed that the highly expressed miR-886.3p in 
combination with lowly expressed miR-22 were associated with the probability of 
EULAR good response (~95%) [74]. This may indicate the responses of miR-22 and 
miR-886.3p to adalimumab treatment in RA. RA patients before TNF-α therapy 
showed a relatively higher miRNA-5196 expression than those treated with anti-
TNF-α therapy and healthy controls [75]. Studies implied that an increase of miR-
155 may result in the upregulation of membrane TNF expression on monocytes and 
the defect of monocyte capacity to differentiate into M2-like anti-inflammatory 
















The relationship between miRNAs expression and RA activity.
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macrophages, which were the clinical characteristics specific to RA. Notably, 
increased miR-155 could be partially reversed by monoclonal anti-TNF antibodies 
[76]. Besides, the expressions of miR-126, miR-148a, miR-29c, miR-30c, miR-17, 
miR-21, miR-223 and let-7b in neutrophil of RA patients were declined after treat-
ment with anti-TNF-α drugs [77]. Obviously, these miRNAs could be the potential 
bio-markers for DMARDs therapy in RA.
Taken together, dynamic changes of miRNAs were not only associated with dis-
ease activity, but were also affected by therapeutic effects. This reflects the potential 
clinical values of miRNAs expression as novel prognostic markers for RA patients, 
in terms of RA management.
5. MiRNA in refractory rheumatoid arthritis
Most patients achieve remission or low disease activity state with effective thera-
pies and treatment strategies. However, about 20–25% of the patients do not reach 
a state of low disease activity, and the causes of refractory rheumatoid arthritis 
(RRA) have not been identified. The RRA may attribute to the epigenetic changes 
accumulated by chronic RA. A large amount of evidence indicated that changes in 
miRNAs can occur either before or after treatment. Therefore, the alterations of 
miRNAs may affect the duration of RA or the therapeutic effect, leading to RRA. 
However, the mechanisms of miRNAs mediating RRA are still largely unknown. 
Up to date, the mechanism of miRNA on RRA has been known to be related to 
the regulation of drug efflux transporters, apoptosis and cell cycle modification. 
Notably, some somatic genes, such as p53, may also influence RA via miRNAs.
ATP-binding cassette (ABC) transporters are located in cell membrane responsi-
ble for transporting endogenous metabolites and xenobiotics across cell membranes 
in an ATP-dependent manner [78]. The high expression levels of ABC transport-
ers were commonly found in cells from the inflammatory area of refractory RA 
patients [79]. These abnormal expressions in RA patients subsequently increased 
drug efflux and caused patients a lower response to treatment. The reduction of 
therapeutic effect of MTX by increased expression of ABCB1 in RA patients is a 
distinguishable example [80]. Importantly, the MTX-treated group showed the 
ABCC1 expression in synovial tissues higher than the untreated group [81]. These 
studies corroborated that the increasing MTX resistance in RA patients may result 
from the upregulations of ABC transporters. Hence, declining ABC transporter 
expression provides a potential solution for reversing drug resistance in RA chemo-
therapy. One of the reasons for miRNAs being as potential therapeutic targets for 
chemoresistant cancers is their regulations on the expression of ABC transporter. 
Research in ovarian cancer demonstrated that miR-522 inhibited ABCB5 in HT29 
colon cancer cells to reverse drug resistance to doxorubicin [82]. ABCG2-mediated 
drug resistance to 5-FU in colon cancer side population cells was overcome by over-
expressed miR-34a via suppressing DLL1 expression [83]. Similarly, ABCB1 (P-gp) 
expression was downregulated by miR-491-3p via directly bound to the 3’-UTR of 
ABCB1 [84]. MiR-214-3p also acts as a tumor suppressor to inhibit chemoresistance 
in retinoblastoma by targeting ABCB1 [85]. MiR-1268a regulated ABCC1-mediated 
drug resistance to temozolomide in glioblastoma [86].
Based on the important role of RAFLS in RA development, most drugs achieve 
the remission of RA by controlling RAFLS-related activities. MiRNA has been 
considered as a potential reason for refractory RA owing to its important role in 
regulating RAFLS mechanisms. On the one side, miRNA promoted the secretion of 
pro-inflammatory cytokines or MMPs; and increased RAFLS proliferation, inva-
siveness, survival and anti-apoptosis. On the other side, they can regulate various 
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intracellular pathways in RAFLS, which commonly include Wnt, NF-κB, JAK/STAT 
and TLRs signaling pathways. For example, reduced miR-20a expression in RASFs 
activated the JAK-STAT3-mediated inflammation, and promoted cell proliferation 
and apoptosis-resistance [87]. The regulation of PI3K/AKT pathway by target-
ing PIK3R2 with miR-126 promoted RA synovial fibroblasts proliferation and 
apoptosis-resistance [88]. In a separate study, miR-650 was down-regulated in RA 
patients compared with patients with joint trauma undergoing joint replacement 
surgery [89]. Further study confirmed that miR-650 targeted AKT2 to promote 
FLS proliferation and migration, and reduce apoptosis. In another example, 
down-regulated miR-375 in an AIA rat model aggravated the inflammation of FLS 
through Wnt signal pathway [90]. Interestingly, the expression level of the same 
miRNA varied in different tissues, along with different functions. One example is 
miR-21, which increased significantly in a rat model of collagen-induced RA with 
the promotion of FLS proliferation via NF-kB pathway [91]. In contrast, the miR-21 
level in RA patients was declined due to the participation in the imbalance of Th17 
and Treg cells [92].
Generally, p53 being as a tumor suppressor regulates many signaling pathways 
like apoptosis, cell cycle, DNA repair, and cellular stress responses by modulating 
the expressions of miRNAs [93]. Since p53 plays important roles in inflammation, 
apoptosis, and cell proliferation, the p53 function lost by gain-of-function (GOF) 
mutation or its low expression influences RA pathogenesis. Similarly, GOF muta-
tion of p53 can confer tumor cell oncogenic properties such as chemoresistance and 
invasion. According to statistical investigations, the mutation rate of p53 gene in 
RA patients was about 50% [94]. In particular, a pro-apoptotic molecule, p53-reg-
ulated apoptosis-inducing protein 1 (p53AIP1) was suppressed by p53 mutation 
(from arginine to glutamine at site 248) in RAFLS, leading to an anti-apoptotic 
effect [95]. However, the mechanisms of p53-mediated apoptosis resistance are yet 
to elucidate.
Typically, wild-type p53 regulates miRNAs to work. For instance, p53 controlled 
cell apoptosis through regulating miRNAs expressions (e.g. miR-34a, miR15a, and 
miR16–1) [93]. In RA patients, miR-15a and miR16–1 initiated anti-apoptosis by 
inhibiting anti-apoptotic molecule B cell lymphoma 2 (Bcl2) [96]. In addition, miR-
34a expression in RA-FLSs was positively related to X-linked inhibitor of apoptosis 
protein (XIAP) expression which induced RAFLS anti-apoptosis [97]. Since p53 
activates all the above-mentioned miRNAs, functionally defective p53 (p53 muta-
tion) may influence RAFLS apoptosis resistance.
Cyr61, which is a secreted and cysteine-rich extracellular matrix (ECM) 
protein produced by RAFLS, is stimulated by IL-17 for FLS proliferation [98]. 
Over-expressed Cyr61 is an important mediator in a malicious cycle, where a high 
level of Cyr61 promotes RAFLS proliferation and Th17 cell differentiation [99]. 
Generally, wild-type p53 from RA patients promoted expression of miR-22 target-
ing the 3-UTR of Cyr61, leading to a decrease of Cyr61 expression [100]. However, 
functional defect of mut-p53 in RA synovial tissue was unable to activate miR-22 
expression, causing abnormally high Cyr61 expression and, in turn, promoted 
RAFLS proliferation and IL-6 production [100]. Thus, a reduced miR-22 level in RA 
synovial tissue and the resulting RRA attributes to somatic mutations of p53.
MiR-155 is also an important regulator in the pathogenesis of RA. Highly 
expressed miR-155 in PBMCs of RA patients was positively related to inflammatory 
cytokine (e.g. TNF-α and IL-1β), RA activity laboratory indicators (CRP, ESR) 
levels and DAS28 respectively [101]. Recent study indicated that mut-p53 increased 
miR-155 expression in breast cancer, which accelerated cell proliferation, epithelial-
mesenchymal-transition (EMT) and invasion [102]. This implied that p53 muta-
tions may affect the process of RA via miR-155 as similar to breast cancer.
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Overall, miRNAs are not only an independent factor that affects the refrac-
tory of RA, but also are an intermediate link of certain gene mutations related to 
RRA. This may provide a new direction for treating refractory RA or reversing 
miRNA-related apoptosis resistance.
6. Conclusions
MiRNA, a non-coding RNA, widely exists in tissue cells and body fluids. It is 
worth mentioning that the studies on miRNA in RA are still limited, but the results 
verify its important role in immune response regulation and sustained inflamma-
tory response to date. SNPs in specific miRNA genes, such as miR-541, are related 
to the high risk of RA development. Moreover, most miRNAs in synovial tissues can 
influence the process of RA by regulating RAFLS proliferation, invasion and apop-
tosis via targeting inflammatory or immune signaling pathways like NF-κB and Wnt 
pathways. Current efforts have confirmed that the expression level and mechanism 
of the same miRNA varies in different tissues or cells from RA. For example, miR-
21 level in PBMCs was declined to regulate Th-Treg balance by targeting STAT3, 
STAT5 and Foxp3, but that in RAFLS was overexpressed to promote proliferation of 
RAFLS through NF-κB signaling pathway. For clinical management, the dynamic 
change of miRNAs can be a bio-marker for monitoring disease activity and thera-
peutic response, as exemplified by the association of high miR-223 level with high 
disease activity and RA relapse. In addition, some miRNAs may play a crucial role in 
regulating refractory RA or drug-resistance RA.
Finally, an increasing extent of data demonstrates the importance of miRNAs to 
the regulation of the RA process, along with its potential developments in bio-
marker discovery and special targets for treatment. Hence, understanding miRNA 
analysis can be served as a diagnostic and/or prognostic tool in an array of inflam-
matory disorders, especially RA.
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